Elanco Animal Health Incorporated (NYSE: ELAN) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $12.9B. The Maz Rating grades it against the other companies in its sector.
Elanco Animal Health Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $25.85, Elanco Animal Health Incorporated trades at 2.5x sales and 2.0x book value, with an EV/EBITDA of 23.9. Over the last twelve months it generated about $5.1B of revenue and a net loss of $149M. It runs a gross margin of 53.5%, an operating margin of 10.0% and a net margin of -2.9%. It shows return on equity of -2.2%, return on invested capital of 4.4% and a free cash flow yield of 3.1%. On the balance sheet: a debt-to-equity ratio of 0.56 and a current ratio of 2.09. Over the past 52 weeks the share price ranged from $19.40 to $27.98, with a beta of 1.72.
Elanco Animal Health Incorporated does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 15 Buy, 5 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Elanco Animal Health Incorporated (ELAN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 31.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.94% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 31.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.94% / 33% · Receivables / Mkt Cap (36m) 9.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 31.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.94% / 33.33% · Receivables / Mkt Cap (24m) 9.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 29.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 3.68% / 33.33% · Receivables / Avg Assets (4Q) 8.06% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 27.8% / 33.33% · (Cash+ST Inv) / Total Assets 3.49% / 33.33% · (Cash+Recv) / Total Assets 11.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Elanco Animal Health Incorporated (ELAN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
No. Elanco Animal Health Incorporated is over the AAOIFI limit on Debt / Mkt Cap (36m).
Elanco Animal Health Incorporated reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.